NBIX
Neurocrine Biosciences Inc
NASDAQ: NBIX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$131.23
+2.43% today
Updated 2026-04-29
Market cap
$13.20B
P/E ratio
28.10
P/S ratio
4.61x
EPS (TTM)
$4.67
Dividend yield
—
52W range
$108 – $160
Volume
1.1M
Neurocrine Biosciences Inc (NBIX) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $389.68M | $276.65M | $118.18M | $70.82M | $144.42M | $138.37M | $195.98M | $154.68M | $243.03M | $474.79M | $365.09M | $817.59M | $993.15M | $1.31B | $1.73B | $2.07B | $2.37B | $3.25B | $3.72B | $4.63B |
| Cash & equivalents | $80.98M | $99.66M | $68.47M | $37.33M | $54.05M | $50.11M | $63.75M | $44.79M | $31.01M | $74.19M | $83.27M | $254.71M | $141.71M | $112.28M | $187.10M | $340.80M | $262.90M | $251.10M | $233.00M | $713.00M |
| Current assets | $193.66M | $182.95M | $81.42M | $55.39M | $133.05M | $132.48M | $189.26M | $148.46M | $198.20M | $384.07M | $310.44M | $554.92M | $737.78M | $831.00M | $1.02B | $972.80M | $1.45B | $1.61B | $1.72B | $2.52B |
| Total liabilities | $74.96M | $157.96M | $81.41M | $66.86M | $125.08M | $78.29M | $41.61M | $34.27M | $34.33M | $50.33M | $50.21M | $445.45M | $512.39M | $669.10M | $608.50M | $698.50M | $660.90M | $1.02B | $1.13B | $1.38B |
| Current liabilities | $20.12M | $29.91M | $26.09M | $19.96M | $52.78M | $47.11M | $15.65M | $11.70M | $15.66M | $25.71M | $30.41M | $54.43M | $88.23M | $565.30M | $186.50M | $245.80M | $537.70M | $654.80M | $507.70M | $743.40M |
| Long-term debt | $49.15M | $108.75M | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $369.62M | $388.50M | $408.81M | $317.90M | $335.10M | — | — | — | — |
| Shareholder equity | $314.72M | $118.70M | $36.77M | $3.95M | $19.34M | $60.08M | $154.37M | $120.41M | $208.70M | $424.45M | $314.88M | $372.14M | $480.76M | $636.90M | $1.13B | $1.37B | $1.71B | $2.23B | $2.59B | $3.25B |
| Retained earnings | $-407.35M | $-614.65M | $-703.26M | $-754.30M | $-762.27M | $-724.70M | $-719.67M | $-765.76M | $-826.30M | $-915.23M | $-1.06B | $-1.20B | $-1.18B | $-1.13B | $-725.40M | $-635.80M | $-406.80M | $-157.10M | $29.20M | $447.70M |
| Accounts receivable | $7.19M | $27000.00 | $39000.00 | — | $4.47M | $1.90M | $14.09M | $23000.00 | — | — | — | $31.13M | $56.24M | $126.58M | $157.10M | $185.50M | $350.00M | $439.30M | $479.10M | $686.80M |
| Inventory | — | — | — | — | — | $0.00 | $-14.09M | $-23000.00 | $0.00 | $0.00 | $0.00 | $-31.13M | $10.86M | $17.29M | $28.00M | $30.50M | $35.10M | $38.30M | $57.40M | $69.00M |
| Goodwill | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | $5.40M | $5.80M | $5.70M | — |